Hudson Bay Capital Management
NRSNW icon

Hudson Bay Capital Management’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Hudson Bay Capital Management’s Portfolio NRSNW Stock Details NRSNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-86,753
Closed -$36.4K – 887
2024
Q1 		$36.4K Hold
86,753
– – ﹤0.01% 621
2023
Q4 		$8.68K Hold
86,753
– – ﹤0.01% 625
2023
Q3 		$13.9K Sell
86,753
-981
-1% -$179 ﹤0.01% 693
2023
Q2 		$20.7K Sell
87,734
-62,266
-42% -$19.6K ﹤0.01% 721
2023
Q1 		$45K Hold
150,000
– – ﹤0.01% 686
2022
Q4 		$30K Hold
150,000
– – ﹤0.01% 796
2022
Q3 		$32K Hold
150,000
– – ﹤0.01% 1016
2022
Q2 		$81K Hold
150,000
– – ﹤0.01% 1042
2022
Q1 		$90K Hold
150,000
– – ﹤0.01% 954
2021
Q4 		$137K Buy
+150,000
New +$134K ﹤0.01% 934

Other funds holding NRSNW

CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hudson Bay Capital Management's NRSNW Position: Q2 2024 in Review

Hudson Bay Capital Management sold out of NeuroSense Therapeutics Warrant (NRSNW) in Q2 2024, closing a stake of 86,753 shares — an estimated $36.4K sold.

Hudson Bay Capital Management first reported a position in NRSNW in Q4 2021 and held it in 10 quarters. The position peaked at $137K in Q4 2021. 4 funds tracked by Wall St. Rank hold NRSNW as of Q2 2024.

  • Hudson Bay Capital Management reported no remaining NeuroSense Therapeutics Warrant position as of Q2 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 86,753 NeuroSense Therapeutics Warrant shares in Q2 2024, an estimated $36.4K.
  • Hudson Bay Capital Management first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and held it in 10 quarters.
  • Hudson Bay Capital Management's NeuroSense Therapeutics Warrant position peaked at $137K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q2 2024.

Based on Hudson Bay Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.